Whole Body MRI in Oncology
Launched by ISTITUTO ROMAGNOLO PER LO STUDIO DEI TUMORI DINO AMADORI IRST S.R.L. IRCCS · Mar 19, 2025
Trial Information
Current as of April 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Whole Body MRI in Oncology," is studying how effective a special type of MRI scan is for patients with certain types of cancers, including lymphoma, advanced prostate cancer, and multiple myeloma, among others. The goal is to see how this full-body imaging test can help doctors track the progress of these conditions. The study involves multiple centers, and all patients will receive care as usual without any extra visits or procedures that aren't part of standard practice.
To be eligible for the trial, patients must be at least 18 years old and have a life expectancy of more than three months. They should also be candidates for a whole-body MRI based on their doctor's recommendation. However, patients with certain medical devices that are unsafe for MRI or those whose MRI tests are of poor quality will not be included. If you decide to participate, you'll be contributing to important research that could improve cancer care for many people.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients candidate to WB-MRI according to clinical practice belonging to the study groups listed above.
- • Participant is willing and able to give informed consent for participation in the study.
- • Male or Female, aged ≥ 18 years.
- • Life expectancy greater than 3 months.
- Exclusion Criteria:
- • Patients with MRI-unsafe prostheses and devices.
- • Patients whose tests are of suboptimal quality, or whose test has been suspended, or is incomplete.
Trial Officials
Alice Rossi
Principal Investigator
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.
About Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.R.L. Irccs
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori (IRST S.R.L. IRCCS) is a leading research institute in Italy dedicated to cancer prevention, diagnosis, and treatment. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it combines clinical excellence with innovative research to advance the understanding and management of oncological diseases. The institute is committed to fostering collaboration among researchers, healthcare professionals, and patients, aiming to translate scientific findings into effective therapeutic strategies. Through its clinical trials, IRST enhances the landscape of cancer care, striving for improved patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, Bo, Italy
Meldola, Fc, Italy
Milano, Mi, Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported